Medios Ag · XETR:ILM1
Medios — Q1 2021 Earnings Presentation
24 slides from Medios's earnings presentation, May 11, 2021
Slide 1: Q1 2021 Results
Q1 2021 Results Matthias Gaertner CEO/CFO May 11, 2021
Slide 2: Agenda
1 Executive summary 2 Financial overview 3 Guidance 2021 4 Appendix 2
Slide 3: Highlights – Record quarter: Next level reached
Executive summary Highlights – Record quarter: Next level reached Ongoing progress in strategy implementation • Exploit synergy potentials and cross-selling opportunities: Led to an expansion of the network from 330 to around 500 specialized partner pharmacies • Look for M&A targets: focus on compou
Slide 4: Q1 2021 – Record quarter in Medios' history
Executive summary Q1 2021 – Record quarter in Medios’ history Revenue €m EBITDA pre¹ €m EBT pre¹ €m • Weaker but persistent Corona effects • Quota system still ongoing – effects reflected in margins • Growing competition between EU countries regarding supply of pharmaceuticals, especially those that
Slide 5: Q1 2021 – Split by segments
Executive summary Q1 2021 – Split by segments Revenue by segment1, 2 EBITDA pre by segment2 5% 24% 76% 95% Pharmaceutical Supply Pharmaceutical Supply Patient-specific Therapies Patient-specific Therapies ¹ External revenue excl. Services segment (€0.1m); 2 EBT without extraordinary expenses: adjust
Slide 6: ESG strategy well under way
Sustainability ESG strategy well under way • Code of conduct published end of 2020 • Implementation of ESG targets in the compensation system of the Executive Board • For the first time publication of • Develop and establish ESG strategy, focus on: “voluntary report” based on CSR-RUG¹ • Environmenta
Slide 7: Financial overview
1 Executive summary 2 Financial overview 3 Guidance 2021 4 Appendix 7
Slide 8: Q1 2021 – Record quarter driven by external growth
Financial overview Q1 2021 – Record quarter driven by external growth In € million Q1 2021 Q1 2020 ∆% Revenue 315.9 162.8 94,0 • Strong revenue growth driven by inorganic COGS¹ 300.4 153.8 growth of Pharmaceutical Supply as key 95.3 contributor ratio in % of revenue 95.1 94.5 • Disproportionate incr
Slide 9: Q1 2021 – Record quarter driven by external growth
Financial overview Q1 2021 – Record quarter driven by external growth Q1 YoY Revenue in €m Q1 2020 Organic Inorganic Q1 2021 Pharmaceutical Supply 148.2 11.8 139.6 299.6 • Compared to a very strong previous thereof Cranach Pharma 0 0 139.6 139.6 year Q1 2020 as a result of stockpiling due to COVID-1
Slide 10: Q1 2021 - Improved margins in both segments
Financial overview Q1 2021 - Improved margins in both segments Pharmaceutical Patient-specific Internal Services and Group Supply Therapies IFRS consolidation In € million Q1 2021 Q1 2020 Q1 2021 Q1 2020 Q1 2021 Q1 2020 Q1 2021 Q1 2020 Revenue (total) 307.8 156.1 17.2 15.7 -9.2 -9.0 315.9 162.8 • Th
Slide 11: Financing power - Strong financial position to invest in future growth
Financial overview Financing power- Strong financial position to invest in future growth As of March 31, 2021 In € million Syndicated loan 62.5 Organic growth Thereof called -31.5 • Up to €10 million to be invested in new labs Cash & cash equivalents 74.2 External growth • M&A strategy: focus on com
Slide 12: Guidance 2021
1 Executive summary 2 Financial overview 3 Guidance 2021 4 Appendix 12
Slide 13: Forecast – Nearly doubling of revenue and jump in earnings
Guidance 2021 Forecast – Nearly doubling of revenue and jump in earnings In € million 2021F¹ 2020 Growth % Group revenue 1,150 – 1,200 626.0 84 – 92 + External growth will be substantially driven by the acquisitions of Cranach Pharma, and Kölsche Blister; additional acquisitions EBITDA pre² 38 – 39
Slide 14: Proven financial track with strong profitable growth
Key financials Proven financial track with strong profitable growth Medios Group IFRS 20161 20172 20182 20192 20202 2021E2 1,150- Pharmaceutical Supply 1,200 Patient-specific Therapies 627 517 10% 10% 328 254 160 12% 90% ++++ 17% 90% 25% 88% 83% Revenue in €m 75% 31-32 Pharmaceutical Supply Patient-
Slide 15: Good plan for organic growth and M&A
Growth strategy Good plan for organic growth and M&A • Establish new labs in Berlin by the end of 2021– to • Ongoing M&A focusing on be able to triple manufacturing capacities • Compounding - increase in capacities for • Expand “blistering” focusing on high-priced drugs enhanced production of indivi
Slide 16: Appendix
1 Executive summary 2 Financial overview 3 Guidance 2021 4 Appendix 16
Slide 17: Key figures
Appendix Key figures in € thousand Q1 2021 Q1 2020 ∆ in % in € thousand Q1 2021 Q1 2020 ∆ in % Revenue 315,908 162,834 94.0 Earnings per share (in €) Pharmaceutical Supply 299,628 148,217 >100.0 Undiluted 0.15 0.15 0.0 Patient-Specific Therapies 16,134 14,541 11.0 Diluted 0.14 0.15 -6.7 Services 145
Slide 18: Consolidated statement of comprehensive income
Appendix Consolidated statement of comprehensive income In € thousand Q1 2021 Q1 2020 Revenue 315,908 162,834 Change in stocks of finished goods and 0,084 0,031 work-in-progress Work performed and capitalized 0,063 0,000 Other income 0,139 0,092 Cost of materials 300,373 153,804 Personnel expenses 4
Slide 19: Consolidated balance sheets
Appendix Consolidated balance sheets Assets in € thousand Mar 31, 2021 FY 2020 Liabilities in € thousand Mar 31, 2021 FY 2020 Non-current assets 227,572 58,232 Equity Intangible assets 202,976 35,237 Subscribed capital 20,265 16,085 Capital reserves 267,810 104,487 Property, plant and 7,123 5,337 Ac
Slide 20: Consolidated cash flow statement Q1 2021 (1/2)
Appendix Consolidated cash flow statement Q1 2021 (1/2) In € thousand Q1 2021 Q1 2020 Cash flow from operating activities Net income for the year 2,841 2,310 Depreciation and amortization on non-current assets 3,835 0,627 Decrease/increase in provisions -0,055 -0,161 Other non-cash expenses 0,322 0,
Slide 21: Consolidated cash flow statement Q1 2021 (2/2)
Appendix Consolidated cash flow statement Q1 2021 (2/2) In € thousand Q1 2021 Q1 2020 Cash flow from investment activities Payments made for investments in intangible assets -0,440 -0,236 Payments from disposals of intangible assets 0,250 0,000 Payments made for investments in property, plant and eq
Slide 22: Contact
Contact Claudia Nickolaus Head of Investor & Public Relations Phone +49 30 232 566 800 ir@medios.ag 22
Slide 23: Disclaimer
Disclaimer This presentation has been produced by Medios AG (the „Company“). The facts and information The forward-looking statements, including but not limited to assumptions, opinions and views of contained herein are as up to date as is reasonably possible and are subject to revision in the the C
Slide 24: Q1 2021 Results
Q1 2021 Results Matthias Gaertner CEO/CFO May 11, 2021